About Us
AuraSense Therapeutics' uniquely engineered Spherical Nucleic Acid (SNA™) constructs possess unparalleled biocompatibility and versatility as therapeutics. They hold great promise for combating the most threatening diseases, including heart disease, cancer, skin conditions and bacterial infection.
SNA™ constructs overcome one of the most difficult obstacles to gene regulation: safe and effective delivery into cells and tissues. SNA™ constructs exhibit high stability, high binding specificity, and unparalleled transfection efficiency into numerous cell and tissue types. Needing no carriers or transfection agents, they provoke minimal immune response and no known toxicity.
SNA™ technology originated in the lab of Professor Chad A. Mirkin at the Northwestern University International Institute for Nanotechnology. The Company's scientific founders and their developments have been the subject of over 60 international and national awards, over 500 publications, and over 450 patents.
Latest News
Nanoparticles Offer 'Open Sesame' Keys to New Drugs and Vaccines
Chicago startups Buzz Referrals, AuraSense get VC funds from state
Chad Mirkin Recognized for the Invention of Spherical Nucleic Acid Technology
AuraSense Therapeutics Secures Series B Equity Investment
Hitting The ‘Off’ Switch On Antibiotic Resistance
Technology